Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. [electronic resource]
Producer: 20011207Description: 2808-16 p. digitalISSN:- 0006-4971
- Animals
- Antineoplastic Agents -- administration & dosage
- Benzamides
- Bone Marrow Cells -- metabolism
- Bone Marrow Transplantation
- DNA-Binding Proteins -- drug effects
- Disease Models, Animal
- Fusion Proteins, bcr-abl -- genetics
- Imatinib Mesylate
- Immediate-Early Proteins -- genetics
- Leukemia, Experimental -- drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukocyte Count
- Mice
- Mice, Inbred BALB C
- Milk Proteins
- Piperazines -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- administration & dosage
- RNA, Messenger -- metabolism
- Retroviridae -- genetics
- STAT5 Transcription Factor
- Spleen -- metabolism
- Suppressor of Cytokine Signaling Proteins
- Survival Rate
- Trans-Activators -- drug effects
- Transduction, Genetic
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.